Generali Investments Towarzystwo Funduszy Inwestycyjnych Beam Therapeutics Inc. Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $157 Billion
- Q1 2025
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 45,000 shares of BEAM stock, worth $771,300. This represents 0.56% of its overall portfolio holdings.
Number of Shares
45,000
Previous 42,000
7.14%
Holding current value
$771,300
Previous $1.04 Billion
15.63%
% of portfolio
0.56%
Previous 0.6%
Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
258Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$170 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$152 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$145 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$131 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$77.8 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.21B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...